NCT00523341View on ClinicalTrials.gov

Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis

PHASE3CompletedINTERVENTIONAL
Enrollment

4,550

Participants

Timeline

Start Date

August 7, 2007

Primary Completion Date

July 19, 2015

Study Completion Date

July 19, 2015

Conditions
OsteopeniaOsteoporosis
Interventions
BIOLOGICAL

Denosumab

Administered by subcutaneous injection once every 6 months.

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT00523341 - Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis | Biotech Hunter | Biotech Hunter